GlassScriptPhysician profile
Matthew Adam Lucks
NPI 1215905724
$1,493.31
in general payments reported to CMS, 2019-2025
22 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $29.34 · 2021: $57.86 · 2022: $366 · 2023: $325 · 2024: $192 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $377.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $162.82 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $138.24 | 2022-2025 | Wegovy |
| Boston Scientific Corporation | $104.94 | 2023-2024 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $102.78 | 2023-2025 | |
| Amgen INC. | $88.91 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $87.23 | 2024-2025 | Camzyos |
| Baxter Healthcare | $66.80 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Angiodynamics, INC. | $65.09 | 2022-2025 | Alphavac |
| Sanofi-Aventis U.S. LLC | $58.66 | 2021-2023 | |
| Medtronic Vascular, INC. | $30.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $23.75 | 2022 | |
| Arbor Pharmaceuticals, INC. | $23.53 | 2019 | |
| Abbott Laboratories | $23.32 | 2025 | Assurity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.32 | 2022 | |
| Impulse Dynamics (USA) INC. | $19.18 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $17.69 | 2021 | |
| Bard Peripheral Vascular, INC. | $15.73 | 2019 | |
| Bridgebio Pharma, INC. | $15.36 | 2025 | Attruby |
| Amarin Pharma, INC. | $13.12 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lucks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.